The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > BUSINESS
BUSINESS
- Zeria Obtains Exclusive Rights in Japan for Iron Deficiency Treatment Ferinject from Vifor Pharma of Switzerland
August 21, 2013
- ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
- M3 to Team Up with Yahoo Japan on Healthcare Advertising Business
August 20, 2013
- Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
- BMKK, AZ Join the Fray in the Domestic Diabetes Market; Will Build Their Foundation on Byetta, Bydureon
August 20, 2013
- Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
- A Record 32 Officials at Drug-related Companies Were Paid Over 100 Million Yen in FY2012; Hiroshi Mitsuhara Was Top-paid Official of a Pharmacy Chain for the 4th Year in a Row
August 16, 2013
- Swiss OKs Schizophrenia Treatment Lurasidone: DSP, Takeda
August 15, 2013
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
- Sitagliptin Filed for Combination Therapy with Glinides: MSD, Ono
August 14, 2013
- Novartis AG to Cease Worldwide Development of Afinitor for Hepatocellular Carcinoma
August 14, 2013
- Chugai Paid 18.1 Billion Yen to Healthcare Professionals in 2012
August 13, 2013
- Novartis’s 11-Year Research Grants to 5 Universities Total 1.1 Billion Yen
August 13, 2013
- JPWA Operating Profit Margin at 0.63%, First Gross Profit Margin Rise Since FY2007
August 13, 2013
- MSD Paid 20.8 Billion Yen to Doctors, Medical Institutions in FY2012
August 13, 2013
- Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
- Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period
August 12, 2013
- Novartis Corrects Third-Party Investigation Report on Diovan Studies
August 12, 2013
ページ
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…